Lipid Lowering by Simvastatin Induces Regression of Human Atherosclerotic Lesions

DOI Web Site 被引用文献13件
  • Roberto Corti
    From the Cardiovascular Biology Research Laboratory (R.C., S.G.W., G.H., J.J.B.), The Cardiovascular Institute (R.C., V.F., Z.A.F., S.G.W., G.H., D.S., J. Wentzel, G.M., J.J.B.), and the Department of Neurology (J. Weinberger), Mount Sinai School of Medicine, New York, NY; and Merck Research Laboratories, Clinical Research, Endocrinology, and Metabolism (M.M.), Rathway, NJ.
  • Valentin Fuster
    From the Cardiovascular Biology Research Laboratory (R.C., S.G.W., G.H., J.J.B.), The Cardiovascular Institute (R.C., V.F., Z.A.F., S.G.W., G.H., D.S., J. Wentzel, G.M., J.J.B.), and the Department of Neurology (J. Weinberger), Mount Sinai School of Medicine, New York, NY; and Merck Research Laboratories, Clinical Research, Endocrinology, and Metabolism (M.M.), Rathway, NJ.
  • Zahi A. Fayad
    From the Cardiovascular Biology Research Laboratory (R.C., S.G.W., G.H., J.J.B.), The Cardiovascular Institute (R.C., V.F., Z.A.F., S.G.W., G.H., D.S., J. Wentzel, G.M., J.J.B.), and the Department of Neurology (J. Weinberger), Mount Sinai School of Medicine, New York, NY; and Merck Research Laboratories, Clinical Research, Endocrinology, and Metabolism (M.M.), Rathway, NJ.
  • Stephen G. Worthley
    From the Cardiovascular Biology Research Laboratory (R.C., S.G.W., G.H., J.J.B.), The Cardiovascular Institute (R.C., V.F., Z.A.F., S.G.W., G.H., D.S., J. Wentzel, G.M., J.J.B.), and the Department of Neurology (J. Weinberger), Mount Sinai School of Medicine, New York, NY; and Merck Research Laboratories, Clinical Research, Endocrinology, and Metabolism (M.M.), Rathway, NJ.
  • Gerard Helft
    From the Cardiovascular Biology Research Laboratory (R.C., S.G.W., G.H., J.J.B.), The Cardiovascular Institute (R.C., V.F., Z.A.F., S.G.W., G.H., D.S., J. Wentzel, G.M., J.J.B.), and the Department of Neurology (J. Weinberger), Mount Sinai School of Medicine, New York, NY; and Merck Research Laboratories, Clinical Research, Endocrinology, and Metabolism (M.M.), Rathway, NJ.
  • Donald Smith
    From the Cardiovascular Biology Research Laboratory (R.C., S.G.W., G.H., J.J.B.), The Cardiovascular Institute (R.C., V.F., Z.A.F., S.G.W., G.H., D.S., J. Wentzel, G.M., J.J.B.), and the Department of Neurology (J. Weinberger), Mount Sinai School of Medicine, New York, NY; and Merck Research Laboratories, Clinical Research, Endocrinology, and Metabolism (M.M.), Rathway, NJ.
  • Jesse Weinberger
    From the Cardiovascular Biology Research Laboratory (R.C., S.G.W., G.H., J.J.B.), The Cardiovascular Institute (R.C., V.F., Z.A.F., S.G.W., G.H., D.S., J. Wentzel, G.M., J.J.B.), and the Department of Neurology (J. Weinberger), Mount Sinai School of Medicine, New York, NY; and Merck Research Laboratories, Clinical Research, Endocrinology, and Metabolism (M.M.), Rathway, NJ.
  • Jolanda Wentzel
    From the Cardiovascular Biology Research Laboratory (R.C., S.G.W., G.H., J.J.B.), The Cardiovascular Institute (R.C., V.F., Z.A.F., S.G.W., G.H., D.S., J. Wentzel, G.M., J.J.B.), and the Department of Neurology (J. Weinberger), Mount Sinai School of Medicine, New York, NY; and Merck Research Laboratories, Clinical Research, Endocrinology, and Metabolism (M.M.), Rathway, NJ.
  • Gabor Mizsei
    From the Cardiovascular Biology Research Laboratory (R.C., S.G.W., G.H., J.J.B.), The Cardiovascular Institute (R.C., V.F., Z.A.F., S.G.W., G.H., D.S., J. Wentzel, G.M., J.J.B.), and the Department of Neurology (J. Weinberger), Mount Sinai School of Medicine, New York, NY; and Merck Research Laboratories, Clinical Research, Endocrinology, and Metabolism (M.M.), Rathway, NJ.
  • Michele Mercuri
    From the Cardiovascular Biology Research Laboratory (R.C., S.G.W., G.H., J.J.B.), The Cardiovascular Institute (R.C., V.F., Z.A.F., S.G.W., G.H., D.S., J. Wentzel, G.M., J.J.B.), and the Department of Neurology (J. Weinberger), Mount Sinai School of Medicine, New York, NY; and Merck Research Laboratories, Clinical Research, Endocrinology, and Metabolism (M.M.), Rathway, NJ.
  • Juan J. Badimon
    From the Cardiovascular Biology Research Laboratory (R.C., S.G.W., G.H., J.J.B.), The Cardiovascular Institute (R.C., V.F., Z.A.F., S.G.W., G.H., D.S., J. Wentzel, G.M., J.J.B.), and the Department of Neurology (J. Weinberger), Mount Sinai School of Medicine, New York, NY; and Merck Research Laboratories, Clinical Research, Endocrinology, and Metabolism (M.M.), Rathway, NJ.

書誌事項

タイトル別名
  • Two Years’ Follow-Up by High-Resolution Noninvasive Magnetic Resonance Imaging

抄録

<jats:p> <jats:bold> <jats:italic>Background—</jats:italic> </jats:bold> Statins are widely used to treat hypercholesterolemia and atherosclerotic disease. Noninvasive MRI allows serial monitoring of atherosclerotic plaque size changes. Our aim was to investigate the effects of lipid lowering with simvastatin on atherosclerotic lesions. </jats:p> <jats:p> <jats:bold> <jats:italic>Methods and Results—</jats:italic> </jats:bold> A total of 44 aortic and 32 carotid artery plaques were detected in 21 asymptomatic hypercholesterolemic patients at baseline. The effects of statin on these atherosclerotic lesions were evaluated as changes versus baseline in lumen area (LA), vessel wall thickness (VWT), and vessel wall area (VWA) by MRI. Maximal reduction of plasma total and LDL cholesterol by simvastatin (23% and 38% respectively; <jats:italic>P</jats:italic> <0.01 versus baseline) was achieved after ≈6 weeks of therapy and maintained thereafter throughout the study. Significant ( <jats:italic>P</jats:italic> <0.01) reductions in maximal VWT and VWA at 12 months (10% and 11% for aortic and 8% and 11% for carotid plaques, respectively), without changes in LA, have been reported. Further decreases in VWT and VWA ranging from 12% to 20% were observed at 18 and 24 months. A slight but significant increase (ranging from 4% to 6%) in LA was seen in both carotid and aortic lesions at these later time points. </jats:p> <jats:p> <jats:bold> <jats:italic>Conclusion—</jats:italic> </jats:bold> The present study demonstrates that maintained lipid-lowering therapy with simvastatin is associated with significant regression of established atherosclerotic lesions in humans. Our observations indicate that lipid-lowering therapy is associated with sustained vascular remodeling and emphasize the need for longer-term treatment. </jats:p>

収録刊行物

  • Circulation

    Circulation 106 (23), 2884-2887, 2002-12-03

    Ovid Technologies (Wolters Kluwer Health)

被引用文献 (13)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ